JP2024038034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038034A5 JP2024038034A5 JP2023216425A JP2023216425A JP2024038034A5 JP 2024038034 A5 JP2024038034 A5 JP 2024038034A5 JP 2023216425 A JP2023216425 A JP 2023216425A JP 2023216425 A JP2023216425 A JP 2023216425A JP 2024038034 A5 JP2024038034 A5 JP 2024038034A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- antigen
- binding fragment
- durvalumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 229950009791 durvalumab Drugs 0.000 claims 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 10
- 206010005003 Bladder cancer Diseases 0.000 claims 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims 9
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 6
- 208000023747 urothelial carcinoma Diseases 0.000 claims 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 2
- 229950007217 tremelimumab Drugs 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 231100000402 unacceptable toxicity Toxicity 0.000 claims 1
- 210000003803 urachus Anatomy 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
| JP2019543851A JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Division JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038034A JP2024038034A (ja) | 2024-03-19 |
| JP2024038034A5 true JP2024038034A5 (enExample) | 2024-05-27 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (enExample) |
| EP (1) | EP3582805A4 (enExample) |
| JP (2) | JP2020507596A (enExample) |
| KR (3) | KR20230145547A (enExample) |
| CN (2) | CN110290803A (enExample) |
| AU (2) | AU2018221822A1 (enExample) |
| CA (1) | CA3052652A1 (enExample) |
| EA (1) | EA201991870A1 (enExample) |
| IL (3) | IL320916A (enExample) |
| MA (1) | MA47509A (enExample) |
| SG (1) | SG11201907211TA (enExample) |
| WO (1) | WO2018152415A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900544T1 (it) * | 2014-05-13 | 2019-11-13 | Medimmune Ltd | Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule |
| IL320916A (en) * | 2017-02-16 | 2025-07-01 | Medimmune Llc | Bladder cancer treatment with anti-PD-L1 antibody |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| CN115667552A (zh) * | 2020-05-21 | 2023-01-31 | 阿斯利康(瑞典)有限公司 | 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| SMT201900544T1 (it) * | 2014-05-13 | 2019-11-13 | Medimmune Ltd | Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| JP7144935B2 (ja) * | 2015-05-29 | 2022-09-30 | ジェネンテック， インコーポレイテッド | 癌のための治療方法及び診断方法 |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| EP3448428A4 (en) * | 2016-04-25 | 2019-11-27 | Medimmune, LLC | COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES |
| IL320916A (en) * | 2017-02-16 | 2025-07-01 | Medimmune Llc | Bladder cancer treatment with anti-PD-L1 antibody |
-
2018
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038034A5 (enExample) | ||
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| JP2017537105A5 (enExample) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| RU2012140447A (ru) | Антиангиогенная терапия для лечения рака яичника | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2013520442A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| JP2020507596A5 (enExample) | ||
| JP2008505143A5 (enExample) | ||
| WO2020200305A1 (zh) | 一种含羟基脲的药物组合物的应用 | |
| JP2015528802A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| CN104138386A (zh) | 柴胡皂苷d对肿瘤多药耐药逆转作用的医药用途 | |
| Sharma et al. | Gliofibroma: mixed glial and mesenchymal tumour. Report of three cases | |
| JPWO2020223702A5 (enExample) | ||
| TWI798243B (zh) | 治療癌症的方法 | |
| JP2020520905A5 (enExample) | ||
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
| CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
| Wang et al. | Tetrandrine alleviates macrophage activation syndrome after CAR-T cell therapy | |
| CN115515571A (zh) | 胰腺癌的治疗方法 | |
| RU2629599C1 (ru) | Способ химиолучевого лечения опухолей прямой кишки и анального канала | |
| TW201420130A (zh) | 溶解有二氧化碳之液狀藥劑及其投藥方法 |